Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system

Pharmacotherapy

Volumn 32, Issue 11, 2012, Pages 981-987

  Spence, Michele M ^a   Nguyen, Lynda M ^b   Hui, Rita L ^c   Chan, James ^c  

^a Pharmacy Outcomes Research Group   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Pharmacy Outcomes Research Group   (United States)

Author keywords

Drug substitution; Drugs; Generic; Tacrolimus; Therapeutic equivalency

Indexed keywords

CREATININE; GENERIC DRUG; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BIOEQUIVALENCE; CARDIAC GRAFT REJECTION; CLINICAL EVALUATION; COST CONTROL; COST OF ILLNESS; CREATININE BLOOD LEVEL; DIZZINESS; DOSE RESPONSE; DREAM; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEART GRAFT; HUMAN; INTEGRATED HEALTH CARE SYSTEM; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LIVER GRAFT; LIVER GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT SAFETY; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; CALIFORNIA; COST SAVINGS; DRUG COSTS; DRUG MONITORING; DRUGS, GENERIC; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; RETROSPECTIVE STUDIES; TACROLIMUS; THERAPEUTIC EQUIVALENCY;

EID: 84871601273     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1130     Document Type: Article

References (20)

1. U.S. Food and Drug Administration. Approved drug products Available from http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction= Search.Label-ApprovalHistory Accessed March 21, 2012
2. U.S. Food and Drug Administration. Orange Book: approved drug products with therapeutic equivalence evaluations. Tacrolimus Available from http://www.accessdata.fda.gov/ scripts/cder/ob/docs/obdetail.cfm?Appl-No = 065461&TABLE 1 = OB-Rx. Accessed March 21, 2012
3. U.S. Food and Drug Administration. Drugs@FDA glossary of terms. Therapeutic equivalence. Available from http://www.fda gov/Drugs/ informationondrugs/ucm079436.htm#T. Accessed March 21, 2012
4. Hogan M. Generic tacrolimus: lack of bioequivalence data in transplant recipients raises concerns. Nephrol Times 2009;2:1
5. Vasquez EM, Min DI. Transplant pharmacists' opinion on generic product selection of critical-dose drugs. Am J Health-Syst Pharm 1999;56:615-21 (Pubitemid 29162924)
6. Ansari MJ, Sayegh MH. Switching immunosuppressive drugs in kidney transplant recipients: "show me the evidence." Saudi J Kidney Dis Transplant 2006;17:149-52
7. Momper JD, Ridenour TA, Schonder KS, Shapiro R, Humar A, Venkataramanan R. The impact of conversion from Prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant 2011;11:1861-7
8. McDevitt-Potter LM, Sadaka B, Tichy EM, Rogers CC, Gabardi S. A multicenter experience with generic tacrolimus conversion. Transplantation 2011;92:653-7
9. Abdulnour HA, Araya CE, Dharnidharka VR. Comparison of generic tacrolimus and Prograf drug levels in a pediatric kidney transplant program: brief communication. Pediatr Transplant 2010;14:1007-11
10. Guleria S, Kamboj M, Chatterjee A, et al. Generic tacrolimus (Pan Graf) in renal transplantation: an experience of 155 recipients in India. Transplant Proc 2008;40:2237-9
11. Kim SJ, Huh KH, Han DJ, et al. A 6-month, multicenter, single- arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation Transplant Proc 2009;41:1671-4
12. Müller H, Solari S, Zuniga C, et al. Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile. Transplant Proc 2008;40:705-7 (Pubitemid 351608658)
13. PDR Staff, eds. Red book: pharmacy's fundamental reference, 2010 ed. Montvale, NJ: Thomson Reuters, 2010
14. Klintmalm GB. Immunosuppression, generic drugs and the FDA. Am J Transplant 2011;11:1765-6
15. Sandoz. Tacrolimus capsules package insert. Princeton, NJ; Sandoz, 2009
16. Ensor CR, Trofe-Clark J, Gabardi S, McDevitt-Potter LM, Shullo MA. Generic maintenance immunosuppression in solid organ transplant recipients. Pharmacotherapy 2011;31:1111-29
17. Klintmalm G. Letter from the president of the American Society of Transplant Surgeons to the Food and Drug Administration on draft guidelines for industry describing productspecific bioequivalence recommendations, 2007. Available from http://www.fda.gov/ohrms/dockets/dockets/07d0168/07d- 0168-c000001-01-vol1.pdf. Accessed March 19, 2012
18. Henney JE. Review of generic bioequivalence studies. JAMA 1999;282(21):1995
19. Davit BM, Nwakama PE, Beuhler GJ, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration Ann Pharmacother 2008;43:1583-97
20. Evans RW, Applegate WW, Briscoe DM, et al. Cost-related immunosuppressive medication nonadherence among kidney transplant recipients. Clin J Am Soc Nephrol 2010;5:2323-8